- Company
- Record number of new homegrown drugs released this year
- by Chon, Seung-Hyun Dec 31, 2021 05:51am
- Domestic pharmaceutical and biopharmaceutical companies this year had received approval for four new drugs. This is the most amount of new drugs released in a single year since the first homegrown drug was introduced in 1999. Major companies with an annual sales record of 1 trillion won such as Yuhan Corp, Celltrion, Hanmi Pharamcetucial, and Da
- Company
- Daewoong's drug targets ₩100 bil market as 2nd P-CAB
- by Kim, Jin-Gu Dec 31, 2021 05:51am
- Daewoong Pharmaceutical succeeded in receiving approval for its potassium-competitive acid blocker (P-CAB) ‘Fexclu (fexuprazan)’ for the treatment of gastroesophageal reflux disease (GERD). It is being predicted that the new drug introduced will unfold a full-fledged competition with HK inno.N’s ‘K-CAB (tegoprazan), a GERD treatment
- Company
- Competition for KRAS targeted anticancer drugs
- by Dec 31, 2021 05:51am
- The development of treatments targeting KRAS mutations in solid cancers, including non-small cell lung cancer, is active. This year alone, seven companies were approved for nine related clinical trials. Amgen, which is leading the competition, is undergoing a domestic permit review. According to the pharmaceutical industry on the 30th, the
- Policy
- Changes in Benefit standards such as diabetes drugs
- by Kim, Jung-Ju Dec 31, 2021 05:50am
- The general principles of diabetes solvents and psychotropic drugs and some of Soliris (Eculizumab)'s detailed recognition criteria and methods for benefits change. Testosterone undecanoate, such as Andriol Testocaps Soft Cap, a male hormone drug, is classified by item, and detailed recognition criteria and methods are deleted. The MOHW an
- Company
- Introduction of oral tx for COVID-19
- by Whang, byung-woo Dec 31, 2021 05:50am
- As the U.S. Food and Drug Administration (FDA) has approved the emergency use of Pfizer's Paxlovid, the entry of oral coronavirus treatments into the market is just around the corner. On the 22nd (local time), the FDA approved the use of Paxlovid at home for high-risk adults, children over the age of 12, and patients with underlying diseas
- Company
- Xospata's drug price negotiation period has been extended
- by Eo, Yun-Ho Dec 30, 2021 05:51am
- Drug price negotiations for the new acute myelogenous leukemia drug Xospata, which aims to be exempted, have passed the year. Astellas Korea and the NHIS conducted drug price negotiations until the 20th to register insurance benefits for Acute Myeloid Leukemia (AML), but decided to extend the negotiation deadline without reaching a conclus
- Company
- K-pharma·biopharmas make great tech export deals this year
- by Chon, Seung-Hyun Dec 30, 2021 05:51am
- Once again, Korean pharmaceutical and biopharmaceutical companies have made great technology export performance this year. Although no mega-deals that amount to top 10 licensing deals were made, technology exports were made in various areas in the industry. Also, performance biopharmaceutical companies stood out this year compared to traditi
- Policy
- Will Boryung succeed in tackling Sprycel’s patent
- by Lee, Tak-Sun Dec 30, 2021 05:51am
- Whether a generic for the second-generation chronic myeloid leukemia treatment ‘Sprycel (dasatinib, BMS)’ will be introduced following generics for the first-generation ‘Gleevec (imatinib mesylate, Novartis)' is gaining attention. If introduced, Sprycel’s generic is expected to greatly improve patient accessibility. According to th
- Policy
- The MFDS plans to approve Daewoong's Fexuprazan
- by Lee, Tak-Sun Dec 30, 2021 05:51am
- Fexuprazan, a new drug for GERD that Daewoong Pharmaceutical has researched and developed for 14 years, is expected to obtain domestic approval soon. When Fexuprazan is released, Daewoong is expected to fill the gap in the PPI-based treatment Nexium. According to the industry on the 28th, the MFDS completed the safety and effectiveness exa
- Company
- Donepezil Patch, which is about to be released
- by Dec 30, 2021 05:51am
- Celltrion's Donerion Patch, the world's first Donepezil patch, is scheduled to be officially released on the market in the first half of next year. The price of the patch system, which is attached twice a week, is expected to be about 5,000 won per patch. According to the pharmaceutical industry on the 28th, Celltrion Pharmaceutical is c
